Deal is latest example of European insurance and pension groups tapping fast-growing asset class
Listing in Spain marks rare bright spot in IPO market and signals healthy return for private equity group
Despite bipartisan distaste, the ‘carried interest’ distortion refuses to die
Co-founder Stephen Schwarzman sees ‘signs of change’ across the region
How global companies have fared since the US president’s inauguration
Donald Trump’s trade war and rapidly mounting government debt have shaken confidence in American assets
Wall Street’s top three private capital groups believe their methods are best, but which will stand the test of time?
The largest private equity group is sticking to a fee-based approach, while Apollo and KKR embrace insurance-powered models
Plus, DoorDash buys Deliveroo and private equity gets in on defence
Promise is similar to a controversial enticement to University of California to halt a flood of redemptions
Progress in ‘tariff diplomacy’ will determine level of danger for economy, says Jonathan Gray
Big asset managers seek to bolster private offerings
US private equity investor takes 22% holding in owner of Aberdeen, Glasgow and Southampton airports
US cloud company seeking blockbuster $32bn IPO had to remedy serious administrative errors in December
Private equity group makes final £489mn approach for listed landlord as investors swoop on sector
Comments from Wall Street bosses come as president’s import tariffs fuel US recession fears
Investment group with rights to songs by Shakira will be ‘fundamentally different’ under unified structure
Private equity group increased dividend payouts 18% in 2024, benefiting several top company executives
Private equity firms prepare to exit investments after being constrained by high interest rates
Asic chair says he has encountered ‘pushback’ from private equity when probing deals
Decision to offload the business comes as private equity groups look to capitalise on a flurry of takeover activity
Global buyout groups often do not know whether ByteDance uses their facilities to exploit a legal loophole to access chips
Anthos Therapeutics was set up by Blackstone Life Sciences after it licensed abelacimab drug from Novartis in 2019
US group has pushed heavily into facilities needed to feed AI boom amid breakneck spending by Big Tech
‘Closing in on max loss’
